Astec Lifesciences Ltd

Astec LifeSciences Limited announced its financial results for the quarter ended June 30, 2026, reporting consolidated total income of Rs 84.3 crore, compared to Rs 91.6 crore in the same quarter of the previous year. The company posted a consolidated loss after tax of Rs 18.7 crore, down from a loss of Rs 33.0 crore in Q1FY26, and achieved EBITDA breakeven compared to an EBITDA loss of Rs 10.5 crore in the prior year, supported by a favorable product mix and improved margins. According to Chairman Vishal Sharma, revenue from Enterprise Products grew 42% year-on-year to Rs 51.8 crore, while revenue from CDMO Products stood at Rs 31.8 crore.

Astec Lifesciences Ltd share price softened by 2.27% to Rs 627.85 after the company's net profit saw a strong growth of 141.42% to Rs 18.71 crore, while revenue from operations nosedived 47.32% to Rs 83.56 crore in Q2FY26 over Q1FY26. The market capitalization of Pesticides & Agrochemicals industry group stocks on BSE stood at Rs 1.92 lakh crore, jumping 30.65%. It has slipped by 2.51% over last one week and eased lower by 6.68% in last one month while the market capitalization of Astec Lifesciences Ltd has eased by 4.74% and 9.98% in the same period respectively. Profit before tax (PBT) of Astec Lifesciences Ltd stood at Rs 18.74 crore in Q2 FY26, plunging by 43.25% year-on-year, and surging by 137.22% quarter-on-quarter. EBITDA came in at Rs 1 crore, crashing by 87.91% YoY and tanking 121.29% sequentially. Total expenses slumped by 40.89% to Rs 95.3 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 76.32 crore, growing marginally by 7.09% YoY, while employee benefits expense was at Rs 16.0 crore, slipping by 1.96% YoY. For the TTM ended FY26, revenue from operations grew 17.53% to Rs 448.15 crore, while net profit plunged by 39.96% to Rs 80.88 crore, compared to previous TTM. EBITDA saw a sharp decline of 7163% to Rs 9.6 crore, and PBT tumbled by 42.55% to Rs 81.0 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 80.71 crore in FY26, as against Rs 8.4 crore in FY25. Astec Lifesciences Ltd nosedived by 27.14% in last one year, underperforming the benchmark BSE Sensex which has eased by 4.36% during the same period.

Net Loss of Astec Lifesciences reported to Rs 18.72 crore in the quarter ended June 2026 as against net loss of Rs 33.04 crore during the previous quarter ended June 2025. Sales declined 8.26% to Rs 83.56 crore in the quarter ended June 2026 as against Rs 91.08 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales83.5691.08 -8 OPM %-0.80-12.07 - PBDT-7.67-21.52 64 PBT-18.74-33.02 43 NP-18.72-33.04 43 Powered by Capital Market - Live

Astec Lifesciences will hold a meeting of the Board of Directors of the Company on 31 July 2026.

Astec Lifesciences announced that the 32th Annual General Meeting(AGM) of the company will be held on 31 July 2026.

Net Loss of Astec Lifesciences reported to Rs 7.76 crore in the quarter ended March 2026 as against net loss of Rs 16.09 crore during the previous quarter ended March 2025. Sales rose 32.70% to Rs 158.62 crore in the quarter ended March 2026 as against Rs 119.53 crore during the previous quarter ended March 2025. For the full year,net loss reported to Rs 80.92 crore in the year ended March 2026 as against net loss of Rs 134.75 crore during the previous year ended March 2025. Sales rose 17.53% to Rs 448.15 crore in the year ended March 2026 as against Rs 381.30 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales158.62119.53 33 448.15381.30 18 OPM %5.774.63 --1.01-17.36 - PBDT3.87-4.08 LP -33.99-97.27 65 PBT-7.90-15.66 50 -78.91-140.99 44 NP-7.76-16.09 52 -80.92-134.75 40 Powered by Capital Market - Live

Astec Lifesciences will hold a meeting of the Board of Directors of the Company on 27 April 2026.

Net Loss of Astec Lifesciences reported to Rs 15.70 crore in the quarter ended December 2025 as against net loss of Rs 40.38 crore during the previous quarter ended December 2024. Sales rose 32.88% to Rs 124.72 crore in the quarter ended December 2025 as against Rs 93.86 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales124.7293.86 33 OPM %3.19-6.12 - PBDT-2.37-13.75 83 PBT-13.59-25.15 46 NP-15.70-40.38 61 Powered by Capital Market - Live

Astec Lifesciences will hold a meeting of the Board of Directors of the Company on 30 January 2026.Powered by Capital Market - Live

Net Loss of Astec Lifesciences reported to Rs 24.43 crore in the quarter ended September 2025 as against net loss of Rs 38.56 crore during the previous quarter ended September 2024. Sales declined 25.20% to Rs 73.72 crore in the quarter ended September 2025 as against Rs 98.55 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales73.7298.55 -25 OPM %-9.07-20.03 - PBDT-13.97-27.07 48 PBT-24.41-38.54 37 NP-24.43-38.56 37 Powered by Capital Market - Live